FDA approves Luxturna gene therapy for inherited vision loss
In a significant advancement for medical science, Luxturna (voretigene neparvovec), developed by Spark Therapeutics, has been approved by the U.S. Food and Drug Administration (FDA) ... Read More
FDA approves Genentech’s lucentis for comprehensive diabetic retinopathy treatment
Genentech, a member of the Roche Group, has received approval from the U.S. Food and Drug Administration (FDA) for its lucentis (ranibizumab injection), making it ... Read More